This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2024 Mar 12;331(10):884-885.

doi: 10.1001/jama.2024.0046.

GLP-1 Receptor Agonists and Gastrointestinal Adverse Events

Karine Suissa¹, Sara J Cromer², Elisabetta Patorno¹

Affiliations

Affiliations

¹ Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, Massachusetts.
² Division of Endocrinology, Massachusetts General Hospital, Boston.

PMID: 38470390
DOI: 10.1001/jama.2024.0046

Comment

GLP-1 Receptor Agonists and Gastrointestinal Adverse Events

Karine Suissa et al. JAMA. 2024.

. 2024 Mar 12;331(10):884-885.

doi: 10.1001/jama.2024.0046.

Authors

Karine Suissa¹, Sara J Cromer², Elisabetta Patorno¹

Affiliations

¹ Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, Massachusetts.
² Division of Endocrinology, Massachusetts General Hospital, Boston.

PMID: 38470390
DOI: 10.1001/jama.2024.0046

No abstract available

PubMed Disclaimer

Comment in

GLP-1 Receptor Agonists and Gastrointestinal Adverse Events-Reply.
Rezaeianzadeh R, Sodhi M, Etminan M. Rezaeianzadeh R, et al. JAMA. 2024 Mar 12;331(10):885-886. doi: 10.1001/jama.2024.0049. JAMA. 2024. PMID: 38470387 No abstract available.

Comment on

Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss.
Sodhi M, Rezaeianzadeh R, Kezouh A, Etminan M. Sodhi M, et al. JAMA. 2023 Nov 14;330(18):1795-1797. doi: 10.1001/jama.2023.19574. JAMA. 2023. PMID: 37796527 Free PMC article.

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions

Substances

Actions

Grants and funding

U01 FD007213/FD/FDA HHS/United States

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Silverchair Information Systems